09.04.2018
Dermapharm Holding SE DE000A2GS5D8
DGAP-News: Dermapharm Holding SE: Dermapharm continued profitable growth in 2017
DGAP-News: Dermapharm Holding SE / Key word(s): Preliminary Results
Dermapharm Holding SE: Dermapharm continued profitable growth in 2017
09.04.2018 / 07:31
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Dermapharm continued profitable growth in 2017
- Revenue in 2017 up 4.9% from last year to EUR 467 million
- Adjusted EBITDA up 9.7% from last year to EUR 113 million
- Adjusted EBITDA margin of 24.2% kept positive trend
- Basis laid for continued profitable growth in 2018 and beyond
Grünwald, April 9, 2018 - Dermapharm Holding SE ("Dermapharm"), a leading
manufacturer of patent-free branded pharmaceuticals for selected markets in
Germany with a growing international presence, published its unaudited
preliminary IFRS financial figures for fiscal year 2017 today. They indicate
that Dermapharm has continued its profitable growth course. The highly
profitable business area branded pharmaceuticals and other healthcare
products made a significant contribution to revenue and earnings growth. The
year also saw important steps taken to continue the company's success story.
Revenue rose on a preliminary basis by 4.9% to EUR 467 million in fiscal
year 2017 (previous year: EUR 445 million). Dermapharm's 2017 earnings
before interest, taxes, depreciation and amortization (EBITDA) significantly
improved, disproportionate to total revenue. Dermapharm increased its EBITDA
by 9.7% to EUR 113 million (previous year: EUR 103 million), adjusted for
one-time costs for IPO preparations of EUR 2.7 million. Dermapharm therefore
once again improved its overall profitability in 2017, achieving an adjusted
EBITDA margin of 24.2% at Group level (previous year: 23.1%). Unadjusted
EBITDA amounted to EUR 110 million, 6.8% higher than last year, with an
unadjusted EBITDA margin of 23.6%.
Dr. Hans-Georg Feldmeier, CEO of Dermapharm Holding SE, comments: "2017 was
a successful year. Dermapharm continued to grow profitably as planned while
consistently advancing the development of new products and acquiring with
bite away(R) and Herpotherm(R) two very promising medical devices that we
will use particularly for international marketing. We also acquired
Trommsdorff and Strathmann, two attractive companies that will expand our
product portfolio in a meaningful direction. Coupled with our IPO in
February 2018, this development provides a very strong basis for continuing
our success story into the future." The acquisition of Strathmann, a
producer of over-the-counter pharmaceuticals (OTC), took place in December
2017 while that of pharmaceutical producer Trommsdorff and its portfolio of
23 different prescription drugs and OTC products was completed in January
2018.
Dermapharm is also constantly striving to develop and launch new
pharmaceuticals and other healthcare products on the market to expand its
product portfolio. Dermapharm's product pipeline currently comprises over 40
ongoing development projects with new products for all areas including
vitamins/minerals/enzymes, dermatologicals, systemic corticoids, women's
healthcare and ophtalmologicals. The pipeline comprises 28 medications and
other healthcare products which are expected to be marketable by 2023. In
view of its international presence, Dermapharm plans to introduce select
products such as bite away(R) and Herpotherm(R) in Italy, Spain, the UK and
the Benelux countries. Subsidiaries in Italy and the UK have already been
established and sales managers appointed. Preparations for the expansion of
Dermapharm's main site in Brehna and the construction of a new production
facility in Neumark am Wallersee, Austria, are also proceeding according to
plan.
Dermapharm will publish its final figures for fiscal year 2017 as well as a
detailed forecast for the current fiscal year with its complete Annual
Report 2017 on April 27, 2018.
Revenue and EBITDA 2017 with previous year comparison (IFRS, preliminary)
in EUR millions 2017 2016 Change
Group revenue 467 445 +4.9%
Adjusted Group EBITDA* 113 103 +9.7%
Adjusted EBITDA margin* (in %) 24.2 23.1 +1.1pp
Group EBITDA 110 103 +6.8%
EBITDA margin (in %) 23.6 23.1 +0.5pp
* Adjusted for one-off costs of EUR 2.7 million for IPO preparations
Company profile:
Dermapharm - Pharmaceutical Excellence "Made in Germany"
Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals
for selected markets in Germany. Founded in 1991, the company is based in
Grünwald near Munich and has its main manufacturing facility in Brehna near
Leipzig. The company's integrated business model comprises in-house
development, in-house production and distribution of pharmaceuticals and
other healthcare products for specifically targeted markets by a medical and
pharmaceutical sales force. Dermapharm holds approximately 900 marketing
authorizations (Arzneimittelzulassungen) for more than 200 active
pharmaceutical ingredients, which are reflected in a broad assortment of
products. This assortment makes the company unique. In addition to Germany,
the company's core markets also include Austria and Switzerland. The company
plans to further expand its international presence. Dermapharm's business
model also includes a parallel import business, which operates under the
"axicorp" brand. Based on revenues, Dermapharm was among the top four
parallel import companies in Germany in 2016.
With a consistent development strategy and numerous successful product and
company acquisitions over the past 25 years, Dermapharm has continuously
optimized its business and provided external growth impulses in addition to
organic growth. Dermapharm intends to continue this profitable growth course
in the future. The company is focusing on three strategic growth drivers:
in-house development of new products, increase of its international
footprint and further acquisitions. These include the acquisition of the
pharmaceuticals manufacturer and distributor Trommsdorff in January 2018,
whose portfolio includes the well-known brands Keltican(R) forte and
Tromcardin(R) complex.
Contact
cometis AG
Claudius Krause
Phone: +49 (0)611-20585528
Fax: +49 (0)611 - 205855-66
Email: [email protected]
---------------------------------------------------------------------------
09.04.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Dermapharm Holding SE
Lil-Dagover-Ring 7
82031 Grünwald
Germany
Phone: +49 (0)89 64 86-0
E-mail: [email protected]
Internet: ir.dermapharm.de
ISIN: DE000A2GS5D8
WKN: A2GS5D
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Stuttgart,
Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
672173 09.04.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Dermapharm Holding SE ISIN: DE000A2GS5D8 können Sie bei EQS abrufen
Gesundheit , A2GS5D , DMP , XETR:DMP